Page last updated: 2024-11-11

bb-83698

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BB-83698: peptide deformylase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9849925
CHEMBL ID1614662
SCHEMBL ID3315627
MeSH IDM0461035

Synonyms (15)

Synonym
bb-83698
chembl1614662 ,
bdbm50174529
36irv2a964 ,
bb83698 ,
cyclopentanepropanamide, n-((1s)-1-((4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)carbonyl)-2,2-dimethylpropyl)-alpha-((formylhydroxyamino)methyl)-, (alphar)-
325795-25-3
unii-36irv2a964
cyclopentanepropanamide, n-((1s)-1-((4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)carbonyl)-2,2-dimethylpropyl)-.alpha.-((formylhydroxyamino)methyl)-, (.alpha.r)-
SCHEMBL3315627
DTXSID60186273
(2r)-n-[(2s)-1-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanamide
Q27256569
PD161572
AKOS040747922

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Dosage Studied

Pneumoniae isolates with reduced susceptibilities to BB-83698 was not observed following treatment with a suboptimal dosing regimen. Dosing in humans proceeded to a predicted efficacious exposure (the area under the concentration-time curve/MIC ratio, up to 184) without any clinically significant adverse effects.

ExcerptRelevanceReference
" pneumoniae isolates with reduced susceptibilities to BB-83698 was not observed following treatment with a suboptimal dosing regimen."( Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia.
Azoulay-Dupuis, E; Bédos, JP; Mohler, J, 2004
)
0.95
" Moreover, BB-83698 dosing in humans proceeded to a predicted efficacious exposure (the area under the concentration-time curve/MIC ratio, up to 184) without any clinically significant adverse effects."( Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor.
Barrowcliffe, S; Clements, JM; Gadd, A; Hevizi, J; Hoch, U; Jiang, V; Johnson, KW; Lofland, D; McColm, J; Moore, C; Moser, H; Patou, G; Ramanathan-Girish, S; Safrin, S; Taupin, P, 2004
)
0.71
" The pharmacokinetics in humans for both of the compounds suggest the possibility of a twice-daily dosing regimen for clinical use."( Therapeutic potential of peptide deformylase inhibitors.
Chen, D; Yuan, Z, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Peptide deformylaseStaphylococcus aureusIC50 (µMol)0.03000.01200.02070.0300AID1303408
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1303413Inhibition of Staphylococcus aureus PDF using formyl-methionine-alanine-serine as substrate assessed as increase in NADH levels at 1 nM by microtiter ELISA2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Identification of novel aminopiperidine derivatives for antibacterial activity against Gram-positive bacteria.
AID1303409Inhibition of Staphylococcus aureus PDF using formyl-methionine-alanine-serine as substrate assessed as increase in NADH levels at 100 nM by microtiter ELISA2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Identification of novel aminopiperidine derivatives for antibacterial activity against Gram-positive bacteria.
AID1303410Inhibition of Staphylococcus aureus PDF using formyl-methionine-alanine-serine as substrate assessed as increase in NADH levels at 30 nM by microtiter ELISA2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Identification of novel aminopiperidine derivatives for antibacterial activity against Gram-positive bacteria.
AID1303408Inhibition of Staphylococcus aureus PDF using formyl-methionine-alanine-serine as substrate assessed as increase in NADH levels by microtiter ELISA2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Identification of novel aminopiperidine derivatives for antibacterial activity against Gram-positive bacteria.
AID1303412Inhibition of Staphylococcus aureus PDF using formyl-methionine-alanine-serine as substrate assessed as increase in NADH levels at 3 nM by microtiter ELISA2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Identification of novel aminopiperidine derivatives for antibacterial activity against Gram-positive bacteria.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1303411Inhibition of Staphylococcus aureus PDF using formyl-methionine-alanine-serine as substrate assessed as increase in NADH levels at 10 nM by microtiter ELISA2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Identification of novel aminopiperidine derivatives for antibacterial activity against Gram-positive bacteria.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (87.50)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.96 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]